Poxel SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yves Decadt
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Immeuble Le Sunway Lyon ARA France 69007
- IPO Date
- Oct 2, 2015
- Website
- poxelpharma.com
- Similar Companies
- Business
- Poxel S.A. (Euronext Paris: POXEL), a clinical-stage biopharmaceutical company, develops innovative treatments targeting cellular energy metabolism for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), type 2 diabetes, and rare metabolic disorders such as adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD); its lead product TWYMEEG (Imeglimin), a first-in-class oral agent addressing mitochondrial dysfunction, is approved and marketed for type 2 diabetes in Japan by partner Sumitomo Pharma Co., Ltd., under a strategic licensing agreement covering Japan, China, South Korea, Taiwan, and nine other Southeast Asian countries, entitling Poxel to royalties and sales-based milestones; PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, advances in Phase 2a for rare diseases including ALD and ADPKD; PXL065 (deuterium-stabilized R-pioglitazone), from the deuterium-modified thiazolidinedione (dTZD) platform, met its primary endpoint in the Phase 2 DESTINY-1 trial for MASH and targets non-genomic pathways including mitochondrial pyruvate carrier inhibition. Founded in 2009 as a spin-off from Merck Serono's metabolic business and headquartered at Immeuble Le Sunway, 259-261 Avenue Jean Jaurès, Lyon, France, Poxel maintains subsidiaries in Boston, Massachusetts, and Tokyo, Japan, with a lean team supporting global operations focused on North America, Europe, and Asia. In recent developments, Poxel entered judicial recovery proceedings in August 2025 following a shareholder vote rejecting key financial delegations, prompting active creditor restructuring negotiations and a draft recovery plan finalized with support from long-standing partner IPF Partners, aimed at cost rationalization, new financing up to €11.25 million from IPF Partners and IRIS, liability settlements, and business continuation including Imeglimin commercialization in Japan, PXL770 advancement in ADPKD, and PXL065 pursuit in hypertrophic cardiomyopathy (HCM); the plan awaits approval from the Lyon Commercial Court and shareholders at the December 11, 2025 Annual General Meeting, which includes votes on capital increases with preferential rights (guaranteed by IPF via debt offset), reserved increases targeting IPF at 29.9% ownership, and warrant issuances, amid a constrained cash runway and prior unsuccessful advanced talks for PXL065 partnering.
Company News
Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
Poxel Publishes Its Financial Results for the First Half of 2025
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
Poxel Reports Revenue for the Third Quarter 2025
Appointment of Yves Decadt as Member of Poxel's Board of Directors
Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading
Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy